Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

Bleeding Disorders market Growth. PORTLAND, OR, UNITED STATES, January 6, 2025 /EINPresswire / -- The global bleeding disorders market is undergoing signif ...

Chad Stevens traveled from Idaho to Omaha's Nebraska Medical Center, where he became the hospital's first patient to receive ...

Home renovations remind columnist G Shellye Horowitz of her efforts to be heard by doctors. In healthcare and in life, she ...

Over one-third of hemophilia patients experience bleeding episodes and joint damage despite prophylactic therapies, indicating a need for more effective treatments. Data from the Adelphi ...

The lower the level of clotting factor VIII, the more serious the bleeding can be. Mild hemophilia A, which involves clotting factor VIII levels of 6% to 40%, rarely causes spontaneous bleeding ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

The bleeding disorder community is served through a ... What are the National Hemophilia Foundation's (NHF) priorities for 2019? Two of NHF’s key priorities for 2019 are access to care and ...

Columnist Jennifer Lynne knows that finding a sense of community can be challenging, but she's also learned it's worth it.

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase I for Unspecified Neurologic Disorders.